ArticleFrontiers in oncology2020
Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Breast cancer and microbiome: a systematic review highlighting challenges for clinical translation.BMC women's health · 2025Pooled it
- Bibliometric and visual analysis of human microbiome-breast cancer interactions: current insights and future directions.Frontiers in microbiology · 2024Pooled it
- Human gut, breast, and oral microbiome in breast cancer: A systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Microbiota as a modulator of drug response: targeting microbial-drug crosstalk in cancer therapy.Gut microbes · 2026Review
- Predictive Biomarkers of Metronomic Chemotherapy Response in Solid Tumors: Chasing an Elusive Signal.Cancers · 2026Review
- Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology.NPJ breast cancer · 2026Review
- Exploring the Gut Microbiota as a Promising Target for Breast Cancer Treatment.Current molecular medicine · 2026Review
- Interaction between the breast tumor microenvironment and gut microbiome.Gut microbes · 2025Review
- Optimizing breast cancer chemotherapy by harnessing gut microbiota with insights from artificial intelligence.NPJ biofilms and microbiomes · 2025Review
- Longitudinal changes in gut microbiota composition during endocrine therapy in hormone receptor-positive breast cancer patients.NPJ breast cancer · 2025Article
- Fecal microbiota transplantation enhanced the effect of chemoimmunotherapy by restoring intestinal microbiota in LLC tumor-bearing mice.BMC immunology · 2025Article
- Gut microbiota interact with breast cancer therapeutics to modulate efficacy.EMBO molecular medicine · 2025Review
- Exploring the relationship between gut microbiota and breast cancer risk in European and East Asian populations using Mendelian randomization.BMC cancer · 2024Article
- Exploring the Relationship between MicroRNAs, Intratumoral Microbiota, and Breast Cancer Progression in Patients with and without Metastasis.International journal of molecular sciences · 2024Article
- Microbiome and cancer: from mechanistic implications in disease progression and treatment to development of novel antitumoral strategies.Frontiers in immunology · 2024Review
- The immunoregulatory role of gut microbiota in the incidence, progression, and therapy of breast cancer.Frontiers in cellular and infection microbiology · 2024Review
- Pharmacomicrobiomics of cell-cycle specific anti-cancer drugs - is it a new perspective for personalized treatment of cancer patients?Gut microbes · 2023Review
- Mendelian randomization analysis revealed a gut microbiota-mammary axis in breast cancer.Frontiers in microbiology · 2023Article
- Gastrointestinal Microbiota and Breast Cancer Chemotherapy Interactions: A Systematic Review.Cureus · 2022Review
- Modulating Microbiota as a New Strategy for Breast Cancer Prevention and Treatment.Microorganisms · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.